Xinghui Ring Material: Jiushi Intelligent commits that within 36 months after the transfer is completed, it will not seek control rights.

robot
Abstract generation in progress

(Source: News Digest)

          After conducting a self-check, the Company has found no instances of violating the principle of fair and timely disclosure of information. The Company has no need to disclose a performance forecast. Except for the accounting firm that provides annual audit services to the Company, the Company has not provided any undisclosed financial data to any other third party.            

On March 31, Xinghui HuanCai (300834.SZ) released an announcement regarding abnormal fluctuations in its stock trading. Within three consecutive trading days, the cumulative closing price increase deviation of the Company’s stock exceeded 30%. According to the relevant provisions of the Shenzhen Stock Exchange, the Company’s stock trading is considered to be an abnormal fluctuation.

In response, the Company’s board of directors conducted verification of relevant matters with the Company’s controlling shareholder and actual controller through telephone and on-site inquiries. First, the Company’s actual controller Chen Yansheng, Chen Dongqiong, Chen Chuanghuang, and their parties acting in concert, Chen Yueping, respectively entered into share transfer agreements with Zelos HK and Jiangsu JiuShi. It was agreed that Chen Dongqiong would transfer 51% of the Company’s shareholder Xinghui Hong Kong held by him to Zelos HK; Chen Yansheng, Chen Chuanghuang, and Chen Yueping would transfer 45% of the Company’s controlling shareholder Xinghui Holdings collectively held by them to Jiangsu JiuShi. Second, this change in equity will not result in any change in the Company’s controlling shareholder or actual controller. JiuShi Intelligent has committed that, after the completion of this equity transfer for 36 months, it will not seek control over the listed company’s controlling rights or actual control rights in any manner, and there is no plan to inject assets into the listed company. In addition, there are no matters in the information previously disclosed by the Company that require correction or supplementation. The Company has not found any major undisclosed information in recent public media reports that may or has already had a significant impact on the trading price of the Company’s stock. In the near term, the Company’s operating situation and both internal and external operating environment have not changed, nor are they expected to change significantly. Meanwhile, after conducting queries, the Company, the controlling shareholder, and the actual controller have no major matters that should be disclosed but have not been disclosed, or other major matters that are in the planning stage. Except for the above-mentioned changes in equity, during the period of the stock’s abnormal movement, there have been no instances of the controlling shareholder or actual controller buying or selling the Company’s stock.

The Company also highlighted related risks: After conducting a self-check, the Company has found no instances of violating the principle of fair and timely disclosure of information. The Company has no need to disclose a performance forecast. Except for the accounting firm that provides annual audit services to the Company, the Company has not provided any undisclosed financial data to any other third party. The Company’s “2025 Annual Report” will be disclosed on April 29, 2026. As for the Company’s specific operating conditions and financial data, please pay attention to the Company’s periodic reports at that time.

Abundant information, precise insights—available on Sina Finance APP

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments